A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
31actual
Sites
21
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-10-12 | actual | When the study began enrolling |
| Primary completion | 2023-10-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-11-30 | estimated | The whole study's end, after follow-up |
| First posted | 2020-06-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-10-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Primary Myelofibrosis
Intervention
- Drug: Fedratinib — also filed as BMS-847943
Primary outcomes
what the primary-completion date above is the date OFMaximum Tolerated Dose (MTD)
measured Up to Cycle 1 (each cycle is 28 days)
Recommended Phase 2 dose (RP2D)
measured Up to Cycle 1 (each cycle is 28 days)
Response Rate (RR)
measured Up to Cycle 6 (each cycle is 28 days)
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed